Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting

The Diabetes Educator

Volumn 28, Issue 6, 2002, Pages 938-957

  Campbell, R Keith ^a   White, John ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

AGING; AMBULATORY CARE; COUNSELING; DISEASE COURSE; HUMAN; INSULIN RESISTANCE; LIFESTYLE; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT EDUCATION; PHARMACIST; PROFESSIONAL STANDARD; REVIEW; RISK FACTOR; UNITED STATES;

AGING; AMBULATORY CARE; COUNSELING; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; OBESITY; PATIENT EDUCATION; PHARMACISTS; PROFESSIONAL ROLE; RISK FACTORS; UNITED STATES;

EID: 0036878387     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572170202800609     Document Type: Article

References (52)

1. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care. 1998;21:310-314.
2. Rifkin H. Diabetic persons see RPhs 5 times more often than they visit physicians. Pharm Times. 1985:27.
3. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics: general information and national estimates on diabetes in the United States, 2000. Available at: http://www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm. Accessed April 25, 2002.
4. Centers for Disease Control. Diabetes: a serious public health problem. At a Glance 2002. Available at: http//vwww.cdc.gov/diabetes/pubs/glance.htm. Accessed April 25, 2002.
5. O'Keefe JH Jr., Miles JM, Harris WH, et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999;74:171-180.
6. Harris Ml, ed. Diabetes in America. Bethesda, Md; National Institutes of Health; 1995. NIH publication 95-1468.
7. Turner NC, Clapham JC. Insulin resistance, impaired glucose tolerance, and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res. 1998;51:36-94.
8. Campbell RK, Bennett J. Assessing diabetes patients’ healthcare needs. Diabetes Educ. 2002;28: 40-44, 49-50.
9. American Diabetes Association. Screening for diabetes. Diabetes Care. 2002;25(suppl 1): S21-S24.
10. Bailey CJ, Insulin resistance and antidiabetic drugs. Biochem Pharmacol. 1999;58:1511-1520.
11. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by change in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;44:1343-1350.
12. KnowlerWC, Barrett-Connor E, Fowler SE, et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
13. Wallberg-Henriksson H. Exercise in the management of non-insulindependent diabetes mellitus. Sports Med. 1998;25:25-35.
14. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes [technical review]. Diabetes Care. 1999; 22:1887-1898.
15. Chiasson JL, Josse RG, Gomis R, et al, for the STOP-NIDDM Trial Research Group. Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: results of a randomized clinical trial: the STOP-NIDDM Trial. Lancet. 2002;359:2002-2007.
16. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
17. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742-749.
18. Goldstein D, Little R, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem. 1986;32(suppl):B64-B70.
19. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002; 25(suppl 1):S33-S49.
20. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
21. United Kingdom Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;353:837-853.
22. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002; 25(suppl 1):S28-S32.
23. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321: 1231-1245.
24. Turner RC, Cull CA, Frighi V, et al, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylureas, metformin, or insulin, in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281: 2005-2012.
25. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25: 815-821.
26. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-121.
27. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient taking rosiglitazone: a case report. Ann Intern Med. 2000;132:121-124.
28. Gouda HE, Khan A, Schwartz J, et al. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med. 2001; 111:584-585.
29. Ravinuthala RS, Nori U. Rosiglitazone toxicity. Ann Intern Med. 2000; 133:658-658.
30. May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;136:449-452.
31. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med. 2001, 135:306-306.
32. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure [letter]. Am J Gastroenterol. 2002;97:502-503.
33. Actos® (pioglitazone hydrochloride) [package insert]. Lincolnshire, III & Indianapolis, Ind: Takeda Pharmaceuticals America & Eli Lilly; January 2002.
34. Avandia® (rosiglitazone maleate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; February 2001.
35. Aronoff S, Rosenblatt S, Braithewaite S, et al, and the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized, placebo-controlled, dose-response study. Diabetes Care. 2000;23:1605-1611.
36. Phillips LS, Grunberger G, Miller E, et al. Onceand twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001; 24:308-315.
37. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. AmJ Med. 2001;111: 10-17.
38. Einhom D, Rendell M, Rosensweig J, et al, and the Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22: 1395-1409.
39. Rosenstock J, Einhom D, Hershon K, et al, and the Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257.
40. FonsecaV, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283: 1695-1702.
41. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Med. 2000;17:40-47.
42. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24: 378-396.
43. Glucophage® (metformin hydrochloride) [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2001.
44. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a doubleblind controlled study. Diabetes Care. 1994;17: 1100-1109.
45. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
46. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the MCE system of intensive diabetes self-management- 2002. Endocr Pract. 2002; 8(suppl 1):40-82.
47. Centers for Disease Control. CDC's diabetes program-statistics: diabetes surveillance, 1999. Chapter 10, figure 10.1. Available at: http://www.cdc.gov/diabetes/statistics/survl99/chapl0/figl.htm. Accessed March 4, 2002.
48. Morbidity and Mortality Weekly Report (MMWR). Recommendations and reports. Strategies for reducing morbidity and mortality from diabetes through health-care system interventions and diabetes self-management education in community settings. Sep 28, 2001/50(RR16): 1-15. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5O16a1/htm. Accessed March 4, 2002.
49. Tankova T, Dakovska G, Koev D. Education of diabetic patients: a one year experience. Patient Educ Couns. 2001;43:139-145.
50. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabetic Med. 2002;19: 279-284.
51. ZoellerJ. Getting paid for diabetes disease management: a guide for pharmacists. American Druggist. 1998; Apr(suppl):2-7.
52. Anonymous. Diabetes pathway slashes length of stay by 26%. Hosp Care Manage. 1999;7:8-8,13-13.